Jefferies Financial Group Inc. Acquires Shares of 769,947 CG Oncology, Inc. $CGON

Jefferies Financial Group Inc. bought a new stake in CG Oncology, Inc. (NASDAQ:CGON) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm bought 769,947 shares of the company’s stock, valued at approximately $54,705,000. Jefferies Financial Group Inc. owned approximately 0.87% of CG Oncology as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently modified their holdings of CGON. Fiduciary Financial Advisors bought a new stake in shares of CG Oncology during the 2nd quarter worth $28,000. NFSG Corp acquired a new stake in shares of CG Oncology in the 1st quarter valued at approximately $34,000. Comerica Bank lifted its stake in CG Oncology by 100.4% in the 4th quarter. Comerica Bank now owns 1,028 shares of the company’s stock valued at $43,000 after purchasing an additional 515 shares during the last quarter. Fifth Third Bancorp bought a new position in CG Oncology in the 1st quarter valued at approximately $74,000. Finally, KBC Group NV acquired a new stake in CG Oncology in the first quarter valued at approximately $78,000. Institutional investors own 26.56% of the company’s stock.

Insider Transactions at CG Oncology

In other news, Director Brian Guan-Chyun Liu purchased 371,085 shares of the business’s stock in a transaction on Thursday, June 25th. The shares were acquired at an average price of $66.87 per share, for a total transaction of $24,814,453.95. Following the completion of the acquisition, the director owned 1,886,236 shares in the company, valued at approximately $126,132,601.32. The trade was a 24.49% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Leonard E. Post sold 5,000 shares of CG Oncology stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $70.00, for a total transaction of $350,000.00. Following the transaction, the director owned 5,000 shares of the company’s stock, valued at $350,000. This represents a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 38,129 shares of company stock valued at $2,738,357. Corporate insiders own 4.80% of the company’s stock.

CG Oncology Stock Performance

NASDAQ:CGON opened at $79.01 on Friday. The firm’s fifty day moving average is $72.78 and its 200-day moving average is $66.40. CG Oncology, Inc. has a 52 week low of $26.22 and a 52 week high of $80.97. The firm has a market cap of $7.00 billion, a P/E ratio of -29.37 and a beta of 0.23.

CG Oncology (NASDAQ:CGON) last announced its earnings results on Thursday, August 6th. The company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.24). The firm had revenue of $1.16 million for the quarter, compared to the consensus estimate of $0.36 million. CG Oncology had a negative return on equity of 25.20% and a negative net margin of 3,602.68%. As a group, sell-side analysts anticipate that CG Oncology, Inc. will post -3.27 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on CGON. JPMorgan Chase & Co. raised their price target on shares of CG Oncology from $91.00 to $96.00 and gave the company an “overweight” rating in a research note on Monday, May 11th. Royal Bank Of Canada decreased their price objective on CG Oncology from $81.00 to $79.00 and set an “outperform” rating for the company in a report on Friday, August 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of CG Oncology in a research report on Friday, July 17th. HC Wainwright reaffirmed a “buy” rating and set a $100.00 target price on shares of CG Oncology in a report on Wednesday, July 29th. Finally, Wolfe Research initiated coverage on CG Oncology in a research report on Tuesday, May 19th. They issued a “peer perform” rating on the stock. Eleven investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $83.18.

CG Oncology Profile

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.